Register Login

Abiopharma

  • Home
  • About
  • Newsroom
  • Company List
  • Events
  • Automated Tools
  • Contact

News list

FDA updates labeling for OLANZAPINE

  • FDA Approval
  • Dec. 31, 2025, 13:45 UTC
  • 43
  • 0 comments

Labeling changes approved for TORRENT PHARMS LTD. Active ingredient: OLANZAPINE. Decision date: 12/02/2025

Comment Full text

FDA regulatory update for TEVIMBRA

  • FDA Approval
  • Dec. 31, 2025, 13:45 UTC
  • 39
  • 0 comments

Administrative update #SUPPL-15 for BEIGENE. Status: Approval. Decision date: 12/02/2025

Comment Full text

FDA approves manufacturing change for CEFAZOLIN SODIUM

  • FDA Approval
  • Dec. 31, 2025, 13:45 UTC
  • 34
  • 0 comments

Manufacturing process update for HIKMA FARMACEUTICA. Submission: SUPPL-34. Decision date: 12/01/2025

Comment Full text

FDA updates labeling for RIFADIN

  • FDA Approval
  • Dec. 31, 2025, 13:45 UTC
  • 41
  • 0 comments

Labeling changes approved for SANOFI AVENTIS US. Active ingredient: RIFAMPIN. Decision date: 12/05/2025

Comment Full text

FDA grants tentative approval for CARBIDOPA AND LEVODOPA from BIOCON PHARMA LIMITED

  • FDA Approval
  • Dec. 31, 2025, 13:45 UTC
  • 37
  • 0 comments

Tentative approval of ANDA #ANDA #220119 for CARBIDOPA,LEVODOPA. Decision date: 12/04/2025

Comment Full text

FDA approves PROPOFOL from NANJING KING FRIEND

  • FDA Approval
  • Dec. 31, 2025, 13:45 UTC
  • 38
  • 0 comments

Final approval of ANDA #ANDA #217945 for PROPOFOL. Decision date: 12/02/2025

Comment Full text

FDA approves ALBUTEROL SULFATE from AMNEAL IRELAND LTD

  • FDA Approval
  • Dec. 31, 2025, 13:45 UTC
  • 34
  • 0 comments

Final approval of ANDA #ANDA #211600 for ALBUTEROL SULFATE. Decision date: 12/01/2025

Comment Full text

FDA approves MACITENTAN from MYLAN

  • FDA Approval
  • Dec. 31, 2025, 13:45 UTC
  • 40
  • 0 comments

Final approval of ANDA #ANDA #211161 for MACITENTAN. Decision date: 12/03/2025

Comment Full text

FDA expands indications for JAYPIRCA

  • FDA Approval
  • Dec. 31, 2025, 13:45 UTC
  • 31
  • 0 comments

LOXO ONCOL receives approval for new indications. Submission: SUPPL-5. Decision date: 12/02/2025

Comment Full text

FDA updates labeling for EPLERENONE

  • FDA Approval
  • Dec. 31, 2025, 13:45 UTC
  • 38
  • 0 comments

Labeling changes approved for RISING. Active ingredient: EPLERENONE. Decision date: 12/04/2025

Comment Full text
  • Previous
  • 42
  • 43
  • 44
  • 45
  • 46
  • Next

Search

News categories

  • Technical Exchange News(13201)
  • Event(6229)
  • SEC News(334177)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(185628)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin